Secondary MGUS after autologous hematopoietic progenitor cell transplantation in plasma cell myeloma: A matter of undetermined significance

Bone Marrow Transplantation

Volumn 47, Issue 9, 2012, Pages 1212-1216

  Manson, G V ^a   Campagnaro, E ^a   Balog, A ^a   Kaplan, D ^a   Sommers, S R ^a   Fu, P ^b   Rajkumar, S V ^c   Lazarus, H M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

autologous hematopoietic progenitor cell transplant; monoclonal gammopathy of undetermined significance; plasma cell myeloma

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; GRAFT RECIPIENT; HUMAN; IMMUNOELECTROPHORESIS; LATENT PERIOD; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; RETROSPECTIVE STUDY; THERAPY EFFECT;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84865957490     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.244     Document Type: Article

References (17)

1. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
2. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
4. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348-2353; quiz 2560.
5. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
6. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
7. Lazarus HM, Sommers SR, Arfons LM, Fu P, Ataergin SA, Kaye NM et al. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: Flow cytometric analysis of hematopoietic progenitor cell grafts. Biol Blood Marrow Transplant 2011; 17: 970-978.
8. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
9. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc Series B 1972; 34: 188-220.
10. Maisnar V, Tichy M, Smolej L, Zak P, Radocha J, Palicka V et al. Isotype class switching after transplantation in multiple myeloma. Neoplasma 2007; 54: 225-228.
11. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with highdose therapy and hematopoietic cell transplantation. Blood 1998; 91: 3518-3523. (Pubitemid 28193907)
12. Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 2000; 25: 723-728. (Pubitemid 30189512)
13. Hall SL, Tate J, Gill D, Mollee P. Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clin Biochem Rev 2009; 30: 113-118.
14. Alejandre ME, Madalena LB, Pavlovsky MA, Facio ML, Corrado C, Milone G et al. Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience. Clin Chem Lab Med 2010; 48: 727-731.
15. Sucak G, Suyani E, Ozkurt ZN, Yegin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol 2010; 28: 180-184.
16. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 2011; 118: 2985-2987.
17. Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein HJ, Alper CA et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989; 74: 2764-2768. (Pubitemid 20007804)